Skip to main content

About your Search

20130124
20130201
Search Results 0 to 1 of about 2
and seems to be laying down the gauntlet for the next fight with president obama so we look forward to some very high-profile interviews coming up. >> and guess what our stock of the day is, yeah, you guessed it. it's apple. that stock is down nearly 11%, nearly 12% right now. first gets worse for the iconic company. overdone, a little overexaggerated, all this selling and how much of this has to do with the loss of steve jobs? >> we'll keep an eye on that for you. keep an eye on the major averages. here's how we stand. the dow was up about 100 points at that peak there. then we started to move lower, and you started to get sweaty palms among bulls. what does this mean? if we close lower, that might not be good. started coming back and now a gain of 44 points. another one of those days where any positive close is another five-year high for the trials going back to the fall of 2010. we're at 13,823. the nasdaq though is going the other direction. blame apple which is 13% of the nasdaq these days. it's down 24 points, the nasdaq is at 3129, and the s&p is up. nope, now it is lower. we're down
of money to develop them. but then again, we all have this problem with keeping health care costs down and obama care wants generic competition for biologics. what's the right road to take there? >> you know, joe, we've been in this industry for over 135 years. for us, we've taken a focus and we pursue both small molecule as well as bioological routes to address some of the most oppressing diseases out there. if you take alzheimer's, we have the biologic but we have a base inhibitor in phase two -- >> would you pay a lobbyist, would you get lobbyists for eli lilly to try to make it that you don't have to have generic competition for biologics, is that something eli lilly would do, or do you go along with it? >> well, remember, in the affordable care act we did get an extension in terms of data protection, as we should be, to at least 12 years. we believe that's very important for us to have a reasonable period to generate return on investment that we make in r&d. we still are the industry that invests the most in r&d, research and development, in this country. we from a policy standpoi
Search Results 0 to 1 of about 2